<DOC>
	<DOCNO>NCT00909519</DOCNO>
	<brief_summary>This phase 1 study 8-day treatment period , randomize , control , double-blind , 3 parallel-groups , monocentric study . The primary objective evaluate effect naproxcinod renal function co-administered furosemide comparison naproxen placebo .</brief_summary>
	<brief_title>Effect Repeated Dosing Naproxcinod Renal Hemodynamic Sodium Balance Healthy Volunteers Before After Single Dose Furosemide</brief_title>
	<detailed_description />
	<mesh_term>Furosemide</mesh_term>
	<mesh_term>Naproxen</mesh_term>
	<mesh_term>Naproxen-n-butyl nitrate</mesh_term>
	<criteria>1 . Healthy , non smoker male subject age 18 35 year ( inclusive ) , Screening visit . 2 . Body Mass Index ( BMI ) strictly 18 30 kg/m² ( inclusive ) body weight≥ 50 kg Screening visit . 3 . Normal physical examination Screening visit . 4 . Normal ECG ( 12lead ) Screening visit , judge Investigator . 5 . At Screening runin period visit , Systolic Blood Pressure ( SBP ) 100 139 mmHg ( inclusive ) Diastolic Blood Pressure ( DBP ) 50 89 mmHg ( inclusive ) . 6 . At Screening runin period visit , HR 45 90 bpm ( inclusive ) . 7 . Subjects must able understand write information sheet informed consent comply study requirement . 8 . Subjects must provide write , date sign informed consent prior study procedure . 1 . A history hypersensitivity reaction ( asthma , rhinitis , urticaria ) aspirin , naproxen NSAIDs ; hypersensitivity contraindication organic nitrate drug hypersensitivity furosemide sinistrine PAH . 2 . Family history hypertension may disqualify subject , judge investigator.. 3 . History clinically relevant gastrointestinal ( gastritis gastric ulcer ) , respiratory , psychiatric , neurologic , kidney , liver , cardiac disease , bleed disorder , disease/condition abnormal physical finding may interfere study objective . The investigator may disqualify subject sound medical psychiatric reason . 4 . History presence ASAT &gt; 40UI/L , ALAT &gt; 40UI/L , serum bilirubin 3 time Upper Limit Normal range Screening visit . 5 . Creatinine clearance inferior/equal 80 ml/min calculate CockcroftGault formula ( Appendix 5 protocol ) Screening visit . 6 . Plasmatic potassium &lt; 3.5 mmole/L Screening visit . 7 . Seropositivity HBs , HBc , HIV 1 HIV 2 Screening visit . 8 . Donations blood , plasma platelet within 3 month prior Screening visit donation plan 3 month follow Day 8 . 9 . Any clinically significant abnormal laboratory value Screening visit . 10 . At Screening visit , 1 minute stand position , drop 20 mmHg SBP 10 mmHg DBP clinical manifestation postural hypotension . 11 . Chronic use drug ( prescription OTC ) within 4 week prior Visit 2 ( single use medication paracetamol headache tolerate low possible dose ) . 12 . Intake Nitric Oxide Synthase Inhibitor within 1 month Screening visit . 13 . History drug addiction alcohol abuse define DSM IVR , diagnostic criterion drug alcohol abuse drug addiction . 14 . Positive drug screening ( opiate , cannabinoids , cocaine , benzodiazepine , amphetamine , barbiturate ) Screening visit . 15 . Current participation participation within 60 day prior Screening visit , another investigational study , include present study previous enrolment naproxcinod study . 16 . In custody due administrative legal decision , tutelage , admit sanitary social institution . 17 . Any direct indirect involvement study conduct staff site family link study site staff .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>June 2011</verification_date>
</DOC>